Syros Pharmaceuticals, Inc.
SYRS
$0.032
-$0.0067-17.31%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 386.00K | 3.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 386.00K | 3.76M |
| Cost of Revenue | 20.53M | 21.95M | 24.66M | 21.50M | 28.28M |
| Gross Profit | -20.53M | -21.95M | -24.66M | -21.12M | -24.52M |
| SG&A Expenses | 5.66M | 5.46M | 6.27M | 5.89M | 7.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.18M | 27.42M | 30.92M | 27.39M | 36.04M |
| Operating Income | -26.18M | -27.42M | -30.92M | -27.01M | -32.28M |
| Income Before Tax | -6.40M | -23.33M | -3.71M | -64.38M | -40.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.40M | -23.33M | -3.71M | -64.38M | -40.14M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.40M | -23.33M | -3.71M | -64.38M | -40.14M |
| EBIT | -26.18M | -27.42M | -30.92M | -27.01M | -32.28M |
| EBITDA | -25.86M | -27.09M | -30.59M | -26.65M | -31.67M |
| EPS Basic | -0.16 | -0.59 | -0.10 | -2.18 | -1.43 |
| Normalized Basic EPS | -0.10 | -0.37 | -0.06 | -1.36 | -0.84 |
| EPS Diluted | -0.16 | -0.59 | -0.10 | -2.18 | -1.43 |
| Normalized Diluted EPS | -0.10 | -0.37 | -0.06 | -1.36 | -0.84 |
| Average Basic Shares Outstanding | 39.34M | 39.27M | 38.98M | 29.54M | 27.99M |
| Average Diluted Shares Outstanding | 39.34M | 39.27M | 38.98M | 29.54M | 27.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |